Home
6494 All Specialties
1559 Arthroplasty
641 Shoulder & Elbow
577 Osteoarthritis
575 Physical Therapy & Rehab
570 Spine
552 Sports Medicine
543 Trauma
412 General Orthopaedics
345 Foot & Ankle
295 Hand & Wrist
198 Cannabis
88 Pediatric Orthopaedics
79 Metabolic Disorders
29 Peri-Operative
29 Tumour
2 Evidence Based Medicine

Conference Reports

Summaries of the best evidence presented at major orthopaedic conferences around the world.

Exclusive Interviews

Original authors are interviewed to verify the veracity of the ACE Report and provide additional information regarding the study’s findings and methodology.

PeerView

Features the top trending OE Content from your network over the past 30 days.

OE Originals
OE Insights
Videos
OE Plus
148 COVID 19 Resource Center
7 Ace Reviews
1 OE Recommends
6 OE PeerView
78 OE Ideas
24 OE World Tour
63 OE Perspectives
48 Conference ACE Reports
159 Exclusive Interviews
CME

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:2 Number:37 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #9045
Ace Report Cover Metabolic Disorders

Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis

How to Cite

OrthoEvidence. Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis. ACE Report. 2017;6(2):37. Available from: https://myorthoevidence.com/AceReport/Report/9045

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)

J Clin Endocrinol Metab. 2016 May;101(5):2023-30

Contributing Authors:
JN Tsai AV Uihlein SM Burnett-Bowie RM Neer NP Derrico H Lee ML Bouxsein BZ Leder

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

94 postmenopausal women with osteoporosis were randomized to receive either teriparatide, denosumab, or a combination of the two treatments. The purpose of this study was to determine the effectiveness of combined therapy with regards to bone microarchitecture and estimated strength. Findings indicated that combination therapy of teriparatide and denosumab significantly improved most volumetric bo...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
Network meta-analysis of current drug options for the treatment of osteoporosis in men
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.